Abstract
Objective: Metformin treatment may induce a decrease/suppression in serum TSH levels, mimicking sub-clinical hyperthyroidism (SHT). The aim of the present study was to retrospectively evaluate changes in several electrocardiographic indices in euthyroid subjects with diabetes who, after starting metformin treatment, developed a low serum TSH as compared to patients with SHT resulting from an underlying thyroid disease or TSH suppressive treatment with L-thyroxine. Design: Heart rate, P wave duration, P wave dispersion, QTmax, QTmin and QT-dispersion were assessed in 23 patients with diabetes treated with metformin before and after 6 months of TS H-suppression and in 31 control patients with SHT. Results: No significant changes in electrocardiographic parameters were observed from baseline to the TSH-suppression measurement. A significant difference in P wave duration (102.9±7.4 vs. 92.1±5.8 ms, p
| Original language | English |
|---|---|
| Pages (from-to) | 252-258 |
| Number of pages | 7 |
| Journal | Hormones |
| Volume | 13 |
| Issue number | 2 |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Atrial fibrillation
- Metformin
- Sub-clinical hyperthyroidism
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Medicine(all)
Cite this
Metformin-induced thyrotropin suppression is not associated with cardiac effects. / Cappelli, Carlo; Rotondi, Mario; Pirola, Ilenia; Agosti, Barbara; Formenti, Ana Maria; De Cata, Pasquale; Salvetti, Massimo; Chiovato, Luca; Castellano, Maurizio.
In: Hormones, Vol. 13, No. 2, 2014, p. 252-258.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Metformin-induced thyrotropin suppression is not associated with cardiac effects
AU - Cappelli, Carlo
AU - Rotondi, Mario
AU - Pirola, Ilenia
AU - Agosti, Barbara
AU - Formenti, Ana Maria
AU - De Cata, Pasquale
AU - Salvetti, Massimo
AU - Chiovato, Luca
AU - Castellano, Maurizio
PY - 2014
Y1 - 2014
N2 - Objective: Metformin treatment may induce a decrease/suppression in serum TSH levels, mimicking sub-clinical hyperthyroidism (SHT). The aim of the present study was to retrospectively evaluate changes in several electrocardiographic indices in euthyroid subjects with diabetes who, after starting metformin treatment, developed a low serum TSH as compared to patients with SHT resulting from an underlying thyroid disease or TSH suppressive treatment with L-thyroxine. Design: Heart rate, P wave duration, P wave dispersion, QTmax, QTmin and QT-dispersion were assessed in 23 patients with diabetes treated with metformin before and after 6 months of TS H-suppression and in 31 control patients with SHT. Results: No significant changes in electrocardiographic parameters were observed from baseline to the TSH-suppression measurement. A significant difference in P wave duration (102.9±7.4 vs. 92.1±5.8 ms, p
AB - Objective: Metformin treatment may induce a decrease/suppression in serum TSH levels, mimicking sub-clinical hyperthyroidism (SHT). The aim of the present study was to retrospectively evaluate changes in several electrocardiographic indices in euthyroid subjects with diabetes who, after starting metformin treatment, developed a low serum TSH as compared to patients with SHT resulting from an underlying thyroid disease or TSH suppressive treatment with L-thyroxine. Design: Heart rate, P wave duration, P wave dispersion, QTmax, QTmin and QT-dispersion were assessed in 23 patients with diabetes treated with metformin before and after 6 months of TS H-suppression and in 31 control patients with SHT. Results: No significant changes in electrocardiographic parameters were observed from baseline to the TSH-suppression measurement. A significant difference in P wave duration (102.9±7.4 vs. 92.1±5.8 ms, p
KW - Atrial fibrillation
KW - Metformin
KW - Sub-clinical hyperthyroidism
UR - http://www.scopus.com/inward/record.url?scp=84899646067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899646067&partnerID=8YFLogxK
M3 - Article
VL - 13
SP - 252
EP - 258
JO - Hormones
JF - Hormones
SN - 1109-3099
IS - 2
ER -